Recommendations for the management of tyrosinaemia type 1

被引：141
|
作者：
de Laet, Corinne [1 ]
Dionisi-Vici, Carlo [2 ]
Leonard, James V. [3 ]
McKiernan, Patrick [4 ]
Mitchell, Grant [5 ]
Monti, Lidia [6 ]
de Baulny, Helene Ogier [7 ]
Pintos-Morell, Guillem [8 ]
Spiekerkoetter, Ute [9 ]
机构：
[1] Univ Childrens Hosp Queen Fabiola, Dept Pediat, Nutr & Metab Unit, Brussels, Belgium
[2] Bambino Gesu Childrens Hosp IRCCS, Dept Pediat Med, Div Metab, Rome, Italy
[3] UCL Inst Child Hlth, London WC1N 1EH, England
[4] Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England
[5] CHU St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada
[6] Bambino Gesu Childrens Hosp IRCCS, Dept Radiol, Unit Hepatobiliary Imaging, Rome, Italy
[7] Hop Robert Debre, Reference Ctr Inherited Metab Dis, F-75019 Paris, France
[8] Badalona Univ Autonoma Barcelona, Univ Hosp Germans Trias & Pujol, Sect Paediat Nephrol Genet & Metab, Dept Paediat, Catalonia, Spain
[9] Univ Childrens Hosp, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany
来源：
ORPHANET JOURNAL OF RARE DISEASES | 2013年 / 8卷
关键词：
Hepatorenal tyrosinaemia; Fumarylacetoacetase; Succinylacetone; Nitisinone; Cirrhosis; Acute live failure; Hepatocellular carcinoma; Low tyrosine diet; LIVER LESION DETECTION; HEREDITARY TYROSINEMIA; NTBC TREATMENT; NITISINONE;
D O I：
10.1186/1750-1172-8-8
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies. The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Mutation screening for tyrosinaemia type I
    Heath, SK
    Gray, G
    Harper, A
    McKiernan, PJ
    Preece, M
    Green, A
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 206 - 206
  • [32] COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006
    Chrzanowski, M.
    Czech, M.
    Hermanowski, T.
    Sykut-Cegielska, J.
    VALUE IN HEALTH, 2008, 11 (06) : A637 - A637
  • [33] Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1
    Bartlett, David C.
    Preece, Mary Anne
    Holme, Elisabeth
    Lloyd, Carla
    Newsome, Phil N.
    McKiernan, Patrick J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (01) : 15 - 20
  • [34] Adult female with severe decompensation of tyrosinaemia type 1 that responds to heme treatment
    Casademunt-Gras, Elena
    Ramos, Analia
    Ruiz, Sabina
    Martin, Mariona
    Joaquin, Clara
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2023, 70 (09): : 612 - 613
  • [35] Success of NTBC in infantile liver failure due to tyrosinaemia type 1.
    McKiernan, PJ
    Preece, MA
    Lindstedt, S
    Holme, E
    Kelly, DA
    HEPATOLOGY, 1998, 28 (04) : 422A - 422A
  • [36] Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?
    Daly, A.
    Gokmen-Ozel, H.
    MacDonald, A.
    Preece, M. A.
    Davies, P.
    Chakrapani, A.
    McKiernan, P.
    JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2012, 25 (02) : 111 - 116
  • [37] Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1
    Yilmaz, Ozlem
    Daly, Anne
    Pinto, Alex
    Ashmore, Catherine
    Evans, Sharon
    Gupte, Girish
    Santra, Saikat
    Preece, Mary Anne
    Mckiernan, Patrick
    Kitchen, Steve
    Ayhan, Nurcan Yabanci
    MacDonald, Anita
    NUTRIENTS, 2020, 12 (04)
  • [38] DIURNAL VARIATION OF PHENYLALANINE CONCENTRATIONS IN TYROSINAEMIA TYPE 1: SHOULD WE BE CONCERNED?
    Daly, A.
    MacDonald, A.
    Gokmen-Ozel, H.
    Preece, M. A.
    Davies, P.
    Chakrapani, A.
    McKiernan, P.
    MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 29 - 29
  • [39] FANCONI SYNDROME SECONDARY TO TYROSINAEMIA TYPE I
    Rufach, A.
    Vique, C.
    Del Toro, M.
    Vazquez, A.
    Vilalta, R.
    Madrid, A.
    Lara, E.
    Nieto, J.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1854 - 1855
  • [40] Cessation of protein substitute in tyrosinaemia type III
    Daly, A.
    Macdonald, A.
    Hopkins, V
    Chakrapani, A.
    Hendriksz, C.
    Vijay, S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 140 - 140
12345